Total trials
267
Active
120
Phase 3
10
Total enrollment
1,265,786
Pipeline matrix
Showing 40 of 41 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Adenosine | — | — | — | — | 2 | ||
| Capecitabine + Radiotherapy | — | — | — | — | — | 1 | |
| Bisoprolol Oral | — | — | — | — | — | 1 | |
| Ramipril Oral Product | — | — | — | — | — | 1 | |
| Dapagliflozin Oral Product | — | — | — | — | — | 1 | |
| Dry plasma | — | — | — | — | — | 1 | |
| Dipyridamole 200 mg | — | — | — | — | — | 1 | |
| Apixaban 5 mg Oral | — | — | — | — | — | 1 | |
| Ticagrelor 90mg twice daily and ASA 75-100 mg daily | — | — | — | — | — | 1 | |
| ASA 75-160 mg daily | — | — | — | — | — | 1 | |
| Optilume | — | — | — | — | — | 1 | |
| busulfan, cyclophosphamide and melphalan, BuCyMel | — | — | — | — | — | 1 | |
| clofarabine, fludarabine and busulfan, CloFluBu | — | — | — | — | — | 1 | |
| Standard systemic therapy | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 1 | |
| Lomustine | — | — | — | — | — | 1 | |
| Technetium | — | — | — | — | — | 1 | |
| IPI1/NIVO3 | — | — | — | — | — | 1 | |
| IPI3/NIVO1 | — | — | — | — | — | 1 | |
| tocilizumab | — | — | — | — | 2 | ||
| Nivolumab | — | — | — | — | 2 | ||
| Pembrolizumab | — | — | — | — | — | 2 | |
| Superparamagnetic Iron Oxide | — | — | — | — | — | 2 | |
| Early start post-transplant vaccination with Gardasil 9® | — | — | — | — | — | 1 | |
| Late post-transplant vaccination with Gardasil 9® | — | — | — | — | — | 1 | |
| Bevacizumab | — | — | — | — | — | 1 | |
| Aflibercept | — | — | — | — | — | 1 | |
| Capsicum Oleoresin | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| Autologous Tumor Infiltrating Lymphocytes | — | — | — | — | — | 3 | |
| Melphalan | — | — | — | — | — | 3 | |
| Interleukin-2 | — | — | — | — | — | 3 | |
| Imatinib 400 MG Oral | — | — | — | — | — | 1 | |
| Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution | — | — | — | — | — | 1 | |
| Cyclosporine | — | — | — | — | — | 1 | |
| Mycophenolate mofetil | — | — | — | — | — | 1 | |
| Rabbit Anti thymocyte globulin | — | — | — | — | — | 1 | |
| Corticosteroids | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Anti-VEGF treatment | — | — | — | — | — | 1 |
1 more active programs hidden
Next readouts
- 2024-07-01
- 2024-12-31
- 2025-03-13
- 2025-10-30
- 2025-12-30
- 2026-10
- 2026-12-31
- 2026-12-31
- 2027-06-30
- 2027-12
Top conditions
- Breast Cancer16
- Rheumatoid Arthritis9
- Obesity6
- Depression6
- Primary Health Care6
- Melanoma5
- Diabetes Mellitus5
- Diabetes Mellitus, Type 15
Frequently asked questions about Vastra Gotaland Region
- How many clinical trials does Vastra Gotaland Region have on ClinicalTrials.gov?
- Vastra Gotaland Region is listed as the lead sponsor on 267 clinical trials in ClinicalTrials.gov, 120 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Vastra Gotaland Region's trials are in Phase 3?
- 10 of Vastra Gotaland Region's trials are in Phase 3, spread across 41 active drug programs.
- What therapeutic areas does Vastra Gotaland Region focus on?
- Vastra Gotaland Region's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Rheumatoid Arthritis, Obesity, Depression, Primary Health Care.
- When are Vastra Gotaland Region's next clinical trial readouts?
- Vastra Gotaland Region has 10 upcoming primary-completion readouts tracked here; the soonest is “Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients”, expected around 2024-07-01.